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Received November 11, 2015; accepted February 2, 2016AbstractBackground: The efficacy and safety of ticagrelor compared with clopidogrel in acute coronary syndrome has not previously been evaluated in
an Eastern Asian population, which is recognized to have a different response to P2Y12 antagonists compared with the Caucasian population in
real-life situations.
Methods: A multicenter retrospective pilot study was performed to evaluate 928 consecutive patients with acute coronary syndrome, receiving
aspirin and one P2Y12 antagonist (324 ticagrelor or 604 clopidogrel). Using propensity score matching, 448 patients were selected and divided
into two equal groups. KaplaneMeier analysis was used to study patient survival and event-free status using the log-rank test. Independent
covariates were identified using univariate in a multivariate Cox proportional hazard model.
Results: In the overall cohort, significant differences were observed for certain variables between the two groups. During the mean 164.3
(±116.4)-day follow-up in the overall cohort, ticagrelor treatment had no significant effect on the primary efficacy endpoint (myocardial
infarction, stroke, or vascular death); however, in the matched cohort, ticagrelor showed a lower incidence of primary endpoint (hazard ratio:
0.56; 95% confidence interval: 0.30e1.04; p ¼ 0.07) and stroke (hazard ratio: 0.15; 95% confidence interval: 0.02e1.24; p ¼ 0.08) with
marginal statistical significance, and a similar bleeding rate. The protective effect of ticagrelor treatment was consistent for all subgroups. More
patients treated with ticagrelor experienced dyspnea (21.0% vs. 11.6%, p ¼ 0.007), and P2Y12 antagonist treatment was consequently
discontinued.
Conclusion: Ticagrelor treatment could provide a marginally favorable effect at the expense of an increased risk of dyspnea in real-life situations.
This pilot study provides a scientific basis to call for a larger, suitably powered Phase 4 prospective or observational study in this ethnic
population.
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Dual antiplatelet therapy with aspirin and clopidogrel is
used in patients with acute coronary syndrome (ACS), owing
in part to an increased incidence of thrombogenesis. This
therapy has been proved to be beneficial both with and without
percutaneous coronary intervention (PCI),1e3 and is endorsed
by numerous clinical management guidelines.4e9 However,
clinical application of clopidogrel is hampered by its phar-
macodynamic characteristics because its biotransformation
into active metabolites results in a slow onset of action, and a
variable response10,11 with a potentially increased risk of stent
thrombosis and myocardial infarction (MI).12 The argument
that clopidogrel treatment in Asian patients may not be as
effective as that in Caucasian patients is ongoing, based on the
observation that the frequency of the cytochrome P450 2C19
loss-of-function allele accompanied by high platelet reactivity
is more prevalent in the Asian population.13
Ticagrelor, a novel oral P2Y12 antagonist that does not
undergo biotransformation to active metabolites, has many
favorable pharmacodynamic characteristics, including rapid
onset of action and being reversible, and consistent inhibition
of platelet function.14,15 In the Platelet Inhibition and Patient
Outcomes (PLATO) study, compared with the treatment with a
therapeutic dose of 75 mg/d clopidogrel, treatment with 90 mg
ticagrelor twice daily significantly reduced the rate of death
from vascular causes, MI, and stroke without increasing the
overall major bleeding, but with an increase in non-procedure-
related bleeding in ACS patients with or without ST-segment
elevation.15 Therefore, certain clinical management guide-
lines recommend ticagrelor over clopidogrel for P2Y12 inhi-
bition in patients with ACS.5,7e9
Recently, the possibility of a paradox with regard to anti-
platelet treatment in the East Asian population has been re-
ported.16,17 Some studies have shown a higher prevalence of
on-treatment platelet reactivity, but with a similar thrombotic
event rate after PCI in East Asian patients compared with
Caucasian patients.16,17 In contrast to ischemic events, the risk
of serious bleeding in the East Asian population appears to be
greater than that in the Caucasian population.16,17 Therefore,
the superior efficacy and acceptable safety profile of ticagrelor
to that of clopidogrel, as demonstrated in the PLATO trial,
may not be reproducible in an East Asian population, partic-
ularly a Chinese population. A recently published study that
enrolled 801 East Asian individuals (90% of whom were
Japanese) showed that the incidence of composite primary
endpoints and PLATO-defined major bleeding tended to be
higher in ACS patients treated with ticagrelor than in those
treated with clopidogrel.18 Based on clinical experience and
evidence with anticoagulants, the expected responses of Jap-
anese and Chinese patients to antithrombotic treatments may
not be similar.19,20 To the best of our knowledge, no previous
studies have investigated the efficacy and safety of ticagrelor
compared with clopidogrel in an Asian population in real-life
situations. Therefore, the present Efficacy and Safety of
Ticagrelor versus Clopidogrel in Acute Coronary Syndrome in
Taiwanese (ESTATE) study aimed to determine whetherticagrelor is superior to clopidogrel for the prevention of
vascular events and death in Taiwanese patients with ACS.
2. Methods2.1. Study populationEligible patients were consecutively enrolled in this
multicenter, retrospective study. The study protocol did not
require informed consent and was approved by the Institu-
tional Review Board of the National Cheng Kung University
Hospital, Tainan, Taiwan (identifier: NCKUH B-ER-104-112)
and Tainan Municipal Hospital, Tainan, Taiwan (identifier:
SCMH 1040801). In order to make a parallel comparison of
ticagrelor versus clopidogrel during the same study period, we
screened eligible patients from July 2013 in the Tainan
Municipal Hospital and from June 2014 in the National Cheng
Kung University Hospital until February 2015. Ticagrelor had
been listed and available in both of these hospitals since the
given dates. The eligible patients were selected according to
the following screening criteria: (1) selection of patients with
discharge codes 410.xx and 411.xx, using ICD-9 version; (2)
limiting the patient population to those with primary or sec-
ondary discharge diagnosis of ACS, including acute ST-
segment-elevation MI (STEMI), non-ST-segment-elevation
MI (NSTEMI), unstable angina, and undifferentiated ACS
(including undetermined MI, apical ballooning syndrome,
coronary spasm with elevated cardiac-specific enzymes, and
typical ST-segment deviation in electrocardiography); (3)
including only those patients who were taking ticagrelor or
clopidogrel on or before discharge; and (4) limiting the
number of patients hospitalized via the emergency department
with an initial manifestation of ACS, symptom onset
<24 hours, and duration of symptoms 10 minutes at rest.
Patients were categorized into two groups based on drug
administration at admission: ticagrelor (n ¼ 324) and clopi-
dogrel (n ¼ 604). The clinical and endpoint data were
collected and recorded by a medical chart review if patients
were regularly followed up in our hospital; however, telephone
calls or direct contact with the participants or their families
was made for patients without regular medical follow-up.
However, the authors received the data in an anonymous
manner with no direct reference to medical charts and no
direct contact with participants or their families.2.2. Outcome measurementThe minimum follow-up period was 1 month and the
maximum 1 year. We performed a prespecified analysis of the
primary PLATO composite efficacy endpoints (death from
vascular causes, MI, or stroke).21 Secondary endpoints
included individual occurrence of components of the primary
PLATO efficacy endpoints. Additional efficacy endpoints
included stent thrombosis, among others.
The primary ESTATE composite safety endpoint was timed
to the first PLATO-defined and PLATO-adjudicated major
bleeding event.21 Occurrences of major, minor, and minimal
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minimal bleeding) and combined major and minor bleeding
events were recorded and compared between groups, as per a
study design similar to that used for PLATO.212.3. Definitions of endpointsDeath from vascular causes was defined as death from
cardiovascular or cerebrovascular causes, including deaths due
to an unknown cause. MI was defined in accordance with the
universal definition proposed in 2012.22 Stent thrombosis was
evaluated according to the Academic Research Consortium
criteria.23 Stroke was defined as the focal loss of neurologic
function caused by an ischemic or a hemorrhagic event with
residual symptoms lasting at least 24 hours or eventually
leading to death.2.4. Statistical analysesAll variables were presented as mean ± standard deviation
and skewed data were reported as the median (interquartile
range). Chi-square or Fisher's exact tests were used for com-
parison of categorical variables between groups, while the
ManneWhitney U test or unpaired Student t test was used for
continuous variables, as appropriate. If more than one
endpoint occurred within the follow-up period, only the first
event was considered. KaplaneMeier analysis was used to
assess patient survival and event-free status, using the log-rank
test (CoxeMantel) to ascertain differences between groups. To
identify the independently predicted role of ticagrelor use for
the occurrence of primary efficacy endpoint, it was adjusted
with variables only mismatched in propensity score matching
cohort using a multivariate Cox proportional-hazard model
using a backward (likelihood ratio) method for stepwise se-
lection of independent covariates. A p value <0.05 was
considered statistically significant.
As a result of the nonrandomized nature of this study,
propensity score analysis was performed in order to minimize
selection bias resulting from differences in clinical charac-
teristics between the groups. The propensity score for the
likelihood of receiving ticagrelor or clopidogrel was computed
using multivariate logistic regression analysis, conditional on
covariates such as age, sex, body weight, smoking status, ACS
spectrum, and the presence of cardiovascular diseases, dia-
betes mellitus, and chronic kidney disease. Then, using the
Greedy 5/ 1 digit match technique, the propensity score was
used to match ticagrelor or clopidogrel patients in a 1:1 ratio.
The kernel densities before and after matching are shown in
Fig. S1. A sensitivity analysis was conducted across various
subgroups to test the robustness of our findings, including
groups classified by sex, age, body weight, hospital type, and
the presence of diabetes mellitus, hyperlipidemia, and chronic
kidney disease. Propensity score matching and subgroup
analysis were performed using SAS software (version 9.1.3;
SAS Institute Inc., Cary, NC, USA). Additional statistical
analyses were performed using SPSS for Windows (version
13.0; SPSS Inc., Chicago, IL, USA).3. Results3.1. Baseline characteristics between groupsA total of 828 patients with ACS were included in this
study. Significant differences were observed between the
two groups for certain baseline characteristics and param-
eters (Table 1). Patients assigned to the ticagrelor group
were significantly younger and had a significantly lower
prevalence of diabetes mellitus, hypertension, hyperlipid-
emia, peripheral artery disease, congestive heart failure,
end-stage renal disease, and previous PCI or bypass surgery.
However, a higher number of patients in this group had a
habit of tobacco smoking. While body weight was signifi-
cantly different between the two groups, body mass index
was well matched. In the ticagrelor group, patients had a
lower Thrombolysis in Myocardial Infarction (TIMI) risk
score and a higher percentage of low-risk Killip classifica-
tion, but higher peak levels of cardiac enzymes and
inflammation markers such as white blood cell and platelet
counts, attributable to an increased incidence of MI.
After propensity score matching, 448 patients were selected
and divided into two equal groups. Baseline characteristics
were well matched, with the exception of a higher percentage
of patients with end-stage renal disease and lower hemoglobin
levels in the clopidogrel group.3.2. Drug treatment parameters and invasive proceduresComparisons of parameters regarding drug treatment and
invasive procedures between the two groups are presented in
Table 2. Prior to propensity score matching in the ticagrelor
group, fewer patients were treated with an angiotensin-
receptor blocker, a calcium-channel blocker, nicorandil, ni-
trate, or an H2-histamine inhibitor, whereas more patients
were undergoing P2Y12 antagonist switch therapy during
hospitalization or discharge. Nevertheless, total exposure time
and adherence rate of the main P2Y12 antagonist were similar
between the two groups. A higher number of patients under-
went invasive diagnostic and therapeutic procedures in the
ticagrelor group. However, fewer patients in this group
received drug-eluting stent deployment.
After propensity score matching, parameters regarding drug
treatment and invasive procedures received were well
matched, with the exception of an increased number of pa-
tients in the ticagrelor group who were on statin treatment,
undergoing P2Y12 antagonist switch therapy, and receiving
coronary angiography or PCI.3.3. Clinical outcomes follow-upThe mean follow-up period was 164.3 ± 116.4 days. Table
3 shows that compared with the clopidogrel group, ticagrelor
treatment did not significantly influence the primary PLATO
efficacy endpoint, whereas it significantly increased total
mortality (11.4% vs. 7.0%, p ¼ 0.02) with a lower incidence
of stroke (0.9% vs. 2.8%, p ¼ 0.06) in the overall cohort.
Table 1
Baseline characteristics and parameters between the two groups.
Propensity score matching () Propensity score matching (þ)
Ticagrelor (n ¼ 324) Clopidogrel (n ¼ 604) p Ticagrelor (n ¼ 224) Clopidogrel (n ¼ 224) p
Age (y) 62.7 ± 13.7 67.7 ± 12.4 <0.001 63.8 ± 13.3 63.7 ± 13.7 0.94
Age 75 y 71 (21.9) 198 (32.8) 0.001 52 (23.2) 59 (26.3) 0.44
Male sex 267 (82.4) 410 (67.9) <0.001 179 (79.9) 178 (79.5) 0.91
DM 114 (35.2) 280 (46.4) 0.001 83 (37.1) 96 (42.9) 0.21
Hypertension 174 (53.7) 382 (63.2) 0.01 124 (55.4) 129 (57.6) 0.63
Hyperlipidemia 134 (41.4) 331 (54.8) <0.001 103 (46.0) 99 (44.2) 0.70
Smoking 179 (55.2) 187 (31.0) <0.001 106 (47.3) 103 (46.0) 0.78
Old MI 28 (8.6) 66 (10.9) 0.27 18 (8.0) 19 (8.5) 0.86
PCI 57 (17.6) 178 (29.5) <0.001 41 (18.3) 42 (18.8) 0.90
CABG 4 (1.2) 28 (4.6) 0.01 4 (1.8) 3 (1.3) >0.99
CHF 15 (4.6) 59 (9.8) 0.01 12 (5.4) 16 (7.1) 0.44
PAD 23 (7.1) 68 (11.3) 0.04 14 (6.3) 16 (7.1) 0.71
Old CVA (ischemic) 27 (8.3) 43 (7.1) 0.50 18 (8.0) 21 (9.4) 0.62
CKD 131 (40.4) 281 (46.5) 0.08 88 (39.3) 88 (39.3) >0.99
ESRD 11 (3.4) 78 (12.9) <0.001 10 (4.5) 32 (14.3) <0.001
Gout 26 (8.0) 49 (8.1) 0.96 20 (8.9) 17 (7.6) 0.61
COPD or asthma 11 (3.4) 20 (3.3) 0.95 10 (4.5) 7 (3.1) 0.46
BW (kg) 68.4 ± 13.2 65.7 ± 12.6 0.003 66.9 ± 11.7 67.5 ± 13.7 0.66
BW <60 kg (%) 69 (21.3) 181 (30.0) 0.01 53 (23.7) 59 (26.3) 0.51
BMI (kg/m2) 25.4 ± 4.1 25.3 ± 4.2 0.58 25.0 ± 3.7 25.1 ± 4.1 0.82
ACS <0.001 0.62
STEMI 137 (42.3) 80 (13.2) 73 (32.6) 78 (34.8)
NSTEMI 116 (35.8) 163 (27.0) 88 (39.3) 78 (34.8)
UAP 66 (20.4) 360 (59.6) 63 (28.1) 68 (30.4)
UACS 5 (1.5) 1 (0.2) 0 0
Killip in STEMI 0.04 0.43
I 88 (64.2) 40 (50.0) 43 (58.9) 40 (51.3)
II 19 (13.9) 12 (15.0) 11 (15.1) 10 (12.8)
III 10 (7.3) 4 (5.0) 5 (6.8) 4 (5.1)
IV 20 (14.6) 24 (30.0) 14 (19.2) 24 (30.8)
TIMI risk score in NSTEMI 3.3 ± 1.2 3.9 ± 1.3 0.04 3.3 ± 1.2 3.7 ± 1.2 0.21
Peak CK level (U/L) 641 (168, 1901) 113 (68, 408) <0.001 473.5 (142.5, 1449) 322 (99, 1318) 0.14
Peak CK-MB level (ng/mL) 42.5 (9.3, 140.5) 4.6 (1.3, 34.6) <0.001 30.9 (6.0, 114.6) 24.0 (4.4, 121.7) 0.75
Initial laboratory tests
Cr (mg/dL) 1.2 (1.0, 1.5) 1.2 (1.0, 1.7) 0.44 1.2 (1.0, 1.5) 1.2 (1.0, 1.7) 0.34
eGFR (mL/min/1.73 m2) 65.2 ± 29.6 58.3 ± 36.2 0.002 64.7 ± 26.9 62.7 ± 47.1 0.59
UA (mg/dL) 6.7 (5.5, 8.2) 6.3 (5.2, 7.4) 0.12 6.7 (5.5, 8.1) 6.7 (5.4, 7.6) 0.92
WBC (103/mL) 10,220 (7872.5, 12,955.8) 8130 (6567.5, 10,900) <0.001 9820 (7475, 12,395) 9900 (7650, 13,000) 0.36
Hb (g/dL) 14.1 ± 2.2 13.2 ± 7.4 0.05 13.9 ± 2.1 13.2 ± 2.5 0.002
PLT (103/mL) 223.5 (185, 260) 208 (170, 258) 0.01 218 (180, 258) 217 (180, 265) 0.91
Data are presented as the mean ± standard deviation, n (%), or median (interquartile range).
ACS ¼ acute coronary syndrome; BMI ¼ body mass index; BW ¼ body weight; CABG ¼ coronary-artery bypass grafting; CHF ¼ congestive heart failure;
CK ¼ creatine kinase; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; Cr ¼ creatinine; CVA ¼ cerebrovascular accident;
DM ¼ diabetes mellitus; eGFR ¼ estimated glomerular filtration rate; ESRD ¼ end-stage renal disease; Hb ¼ hemoglobin; MI ¼ myocardial infarction;
NSTEMI ¼ non-ST-segment-elevation myocardial infarction; PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; PLT ¼ platelet;
STEMI ¼ ST-segment-elevation myocardial infarction; TIMI = Thrombolysis in Myocardial Infarction; UA ¼ uric acid; UACS ¼ undifferentiated acute coronary
syndrome; UAP ¼ unstable angina pectoris; WBC ¼ white blood cell.
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ticagrelor group had a lower incidence of the primary PLATO
efficacy endpoint (hazard ratio: 0.56; 95% confidence interval:
0.30e1.04; p ¼ 0.07) and stroke (hazard ratio: 0.15; 95%
confidence interval: 0.02e1.24; p ¼ 0.08) with marginal sta-
tistical significance (Table 3 and Fig. 1). There was no sig-
nificant difference in the incidence of vascular death, MI, total
death, or stent thrombosis between the two groups. In the
propensity matching cohort, a subgroup analysis and evalua-
tion of seven clinical variables to determine the effect of
ticagrelor versus clopidogrel on the occurrence of the primary
PLATO efficacy endpoint showed that a protective effect infavor of ticagrelor treatment was consistent across all sub-
groups (Fig. 2).
There was no significant difference in the incidence of
primary safety endpoint, fatal bleeding, or intracranial hem-
orrhage between the two groups in either the overall or the
propensity-matched cohort (Table 4). However, ticagrelor
treatment caused a higher rate of minor, minimal, or all
bleeding before matching (Table 4). In the propensity-matched
cohort, there was no significantly different rate of bleeding,
including minor, minimal, and all bleeding (6.3% vs. 3.1%,
p ¼ 0.12; 10.3% vs. 6.7%, p ¼ 0.18; 19.6% vs. 14.3%,
p ¼ 0.13, respectively), between both groups.
Table 2
Drug treatment and procedure parameters between the two groups.
Propensity score matching () Propensity score matching (þ)
Ticagrelor (n ¼ 324) Clopidogrel (n ¼ 604) p Ticagrelor (n ¼ 224) Clopidogrel (n ¼ 224) p
P2Y12 antagonist before ACS 0.06 0.13
Ticagrelor 2 (0.6) 1 (0.2) 2 (0.9) 0
Clopidogrel 16 (4.9) 95 (15.7) 12 (5.4) 24 (10.7)
Ticlodipine 0 0 0 0
Naïve 306 (94.4) 508 (84.1) 210 (93.8) 200 (89.3)
Other drugs used in hospital
Aspirin 297 (91.7) 558 (92.4) 0.70 206 (92.0) 207 (92.4) 0.86
UFH 296 (91.4) 530 (87.7) 0.09 206 (92.0) 199 (88.8) 0.26
GP IIb/IIIa antagonist 3 (0.9) 4 (0.7) 0.70 1 (0.4) 4 (1.8) 0.37
BB 158 (48.8) 332 (55.0) 0.07 114 (50.9) 132 (58.9) 0.09
ACEI 105 (32.4) 168 (27.8) 0.14 32 (32.6) 87 (38.8) 0.17
ARB 44 (13.6) 144 (23.8) <0.001 33 (14.7) 37 (16.5) 0.60
Statin 253 (78.1) 460 (76.2) 0.51 176 (78.6) 156 (69.6) 0.03
Fibrate 5 (1.5) 10 (1.7) 0.90 3 (1.3) 4 (1.8) >0.99
CCB 74 (22.8) 241 (39.9) <0.001 53 (23.7) 60 (26.8) 0.45
Nicorandil 44 (13.6) 126 (20.9) 0.01 27 (12.1) 35 (15.6) 0.27
Nitrate 76 (23.5) 190 (31.5) 0.01 53 (23.7) 53 (23.7) >0.99
Warfarin 5 (1.5) 10 (1.7) 0.90 3 (1.3) 5 (2.2) 0.72
NOAC 2 (0.6) 4 (0.7) 0.94 2 (0.9) 2 (0.9) >0.99
PPI 18 (5.6) 43 (7.1) 0.36 14 (6.3) 18 (8.0) 0.46
H2I 20 (6.2) 72 (11.9) 0.01 14 (6.3) 25 (11.2) 0.07
Switching initial P2Y12 antagonist 14 (4.3) 6 (1.0) 0.001 12 (5.4) 4 (1.8) 0.04
Switching discharge P2Y12 antagonist 37 (11.4) 14 (2.3) <0.001 25 (11.2) 9 (4.0) 0.004
Total exposure of the main P2Y12 antagonist (d) 160.4 ± 123.7 152.2 ± 111.5 0.32 155.7 ± 122.0 142.0 ± 113.5 0.22
Adherence to the main P2Y12 antagonist
a 93.7 ± 58.4 97.4 ± 13.1 0.27 90.9 ± 24.5 96.1 ± 16.7 0.01
Reperfusion strategy in STEMI 0.01 0.06
Lysis 0 0 0 0
PCI 135 (98.5) 72 (90.0) 72 (98.6) 71 (91.0)
Lysis/PCI () 2 (1.5) 8 (10.0) 1 (1.4) 7 (9.0)
Primary PCI in STEMI 134 (97.8) 72 (90.0) 0.02 71 (97.3) 71 (91.0) 0.17
D-2-B time in primary PCI (min) 72 (57.8, 100.8) 67 (55.3, 91.8) 0.27 72 (60, 103) 66 (55, 93) 0.30
PCI in NSTEMI (n ¼ 710) 161 (85.6) 385 (73.8) 0.001 127 (84.1) 101 (69.2) 0.002
CAG in hospital 318 (98.1) 525 (86.9) <0.001 218 (97.3) 198 (88.4) <0.001
PCI in hospital 287 (88.6) 452 (74.8) <0.001 195 (87.1) 167 (74.6) 0.001
Stent deployment 271 (83.6) 416 (68.9) <0.001 185 (82.6) 160 (71.4) 0.01
DES in stenting 99 (36.5) 213 (51.2) <0.001 68 (36.8) 71 (44.4) 0.26
CABG in hospital 12 (3.7) 16 (2.6) 0.37 12 (5.4) 8 (3.6) 0.36
Mean FU (d) 179.8 ± 125.1 156.0 ± 110.6 0.004 176.1 ± 124.6 148.0 ± 112.9 0.01
Data are presented as mean ± standard error, n (%), or median (interquartile range).
ACEI ¼ angiotensin-converting enzyme inhibitor; ACS ¼ acute coronary syndrome; ARB ¼ angiotensin-receptor blockade; BB ¼ beta-blockade;
CAG ¼ coronary angiography; CCB ¼ calcium-channel blocker; DES ¼ drug-eluting stent; D-2-B ¼ door-to-balloon; FU ¼ follow-up; GP ¼ glycoprotein;
H2I ¼ H2-histamine inhibitor; NOAC ¼ novel oral anticoagulant; PCI ¼ percutaneous coronary intervention; PPI ¼ proton-pump inhibitor; UFH ¼ unfractionated
heparin.
a Adherence to the main P2Y12 antagonist ¼ the treatment duration of main P2Y12 antagonist/supposed treatment duration of P2Y12 antagonist in ACS.
Table 3
Primary and secondary efficacy endpoints between the two groups during the follow-up period.
Propensity score matching () Propensity score matching (þ)
Ticagrelor (n ¼ 324) Clopidogrel (n ¼ 604) p Ticagrelor (n ¼ 224) Clopidogrel (n ¼ 224) HR (95% CI) pa
Primary PLATO efficacy endpoint 28 (8.6) 55 (9.1) 0.81 16 (7.1) 26 (11.6) 0.56 (0.30e1.04) 0.07
Vascular death 20 (6.2) 30 (5.0) 0.44 10 (4.5) 16 (7.1) 0.57 (0.26e1.27) 0.17
MI 9 (2.8) 14 (2.3) 0.67 7 (3.1) 6 (2.7) 1.02 (0.34e3.05) 0.97
Stroke 3 (0.9) 17 (2.8) 0.06 1 (0.4) 6 (2.7) 0.15 (0.02e1.24) 0.08
Ischemic 2 (66.7) 11 (64.7) 1 (100) 5 (83.3)
Hemorrhagic 1 (33.3) 6 (35.3) 0 1 (16.7)
Unknown 0 0 0 0
Total mortality 37 (11.4) 42 (7.0) 0.02 22 (9.8) 20 (8.9) 0.98 (0.53e1.79) 0.94
Stent thrombosis 1 (0.3) 4 (0.7) 0.66 0 1 (0.4) 0.02 (0e143,955.8) 0.61
Data are presented as mean ± standard deviation, n (%), or median (interquartile range).
CI ¼ confidence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; PLATO ¼ the Study of Platelet Inhibition and Patient Outcomes.
a The p values were calculated by means of Cox regression analysis.
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intestinal tract in both overall and propensity-matched cohorts,
regardless of whether patients were treated with ticagrelor or
clopidogrel (Table 4). Ecchymosis on the skin was observed
with ticagrelor treatment, and an unknown bleeding site in the
gastrointestinal tract was observed with clopidogrel treatment.
A higher number of patients treated with ticagrelor expe-
rienced dyspnea as compared with those treated with clopi-
dogrel in both overall (25.0% vs. 14.6%, p < 0.001) and
propensity-matched (21.0% vs. 11.6%, p ¼ 0.01) cohorts
(Table 4). Furthermore, the incidence of dyspnea-related
discontinuation of P2Y12 antagonist treatment tended to be
higher in the ticagrelor group by propensity score matching.
Interestingly, a significantly higher number of patients un-
derwent drug switching or discontinuation during P2Y12
antagonist treatment in the ticagrelor group in both overall
(21.6% vs. 15.6%, p ¼ 0.02) and propensity-matched (16.5%
vs. 4.5%, p < 0.001) cohorts (Table 4). The most common
cause of drug switching or discontinuation was bleeding in the
ticagrelor group and an unknown cause in the clopidogrel
group (Table 4).3.4. Independent predictors of the primary PLATO
efficacy endpointBy univariate analysis, 15 univariables ( p < 0.1), including
ticagrelor use, were associated with the occurrence of the
primary endpoint. To identify independent predictors of the
primary PLATO efficacy endpoint and to avoid over-
adjustment and collinearity, owing to the low incidence of
total primary events, ticagrelor use was adjusted with end-
stage renal disease and statin use only because they wereFig. 1. Event-free survival of primary composite efficacy endpoint stratified by tica
propensity matching cohort. HR ¼ hazard ratio.mismatched in the propensity score matching cohort and
showed statistical insignificance in multivariate analysis
(Table 5). To exclude the potential impact of end-stage renal
disease on the clinical outcome, we repeated analysis in 406
patients without any history of end-stage renal disease and
found that ticagrelor still has a marginally protective effect on
the occurrence of the primary endpoint (Table S1).
4. Discussion
The current study is the first of its kind that investigated the
efficacy and safety of ticagrelor versus clopidogrel in patients
with ACS in Asia (including Taiwan) in a real-life clinical
setting. Our data show that ticagrelor treatment has a
marginally favorable effect on the occurrence of the composite
outcome, including MI, stroke, or vascular death, with a
similar incidence of major bleeding or other bleeding at the
expense of a significantly higher incidence of dyspnea.
According to our results in the overall cohort, we can
appreciate the prescription behavior for P2Y12 antagonists in a
real-world setting. Physicians in this region prefer ticagrelor
for the treatment of ACS patients with MI (STEMI or
NSTEMI) owing to a lower baseline cardiovascular risk as
well as a lower bleeding risk. This is partly attributable to
awareness of the pharmacodynamics, clinical efficacy, and
safety outcomes from previous trials. Previous studies have
shown that cardiac enzymes and inflammatory biomarkers are
significantly higher in patients with MI.24,25 Therefore, in the
present study, peak levels of cardiac enzymes after ACS and
inflammatory biomarkers at baseline were much higher in
patients treated with ticagrelor. In Taiwan,26 primary PCI and
early invasive strategies are the main management approachesgrelor or clopidogrel use: KaplaneMeier analysis using the log-rank test in the
Fig. 2. Subgroup analysis of the effect of ticagrelor versus clopidogrel on the occurrence of the primary composite efficacy endpoint by evaluating seven clinical
variables. BW ¼ body weight; CI ¼ confidence interval; CKD ¼ chronic kidney disease.
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patients receive bare-metal stent deployment more frequently
than patients with other coronary artery diseases.26 Therefore,
from our perspective, it is easy to understand why a higher
number of invasive diagnostic and interventional procedures
with bare-metal stent deployment are performed in the tica-
grelor group. However, it is not clear as to why fewer patients
in the ticagrelor group received guideline-directed medial
therapy, and we can only speculate that this could be attrib-
utable to selection bias.
In the overall cohort, there were markedly heterogeneous
background characteristics, diverse medications, and treat-
ment procedures between the groups; this probably
confounded the comparison of the efficacy and safety effects.
Using propensity score matching, our data appear to be in
agreement with those of the PLATO trial15 and support the
notion that ticagrelor might be more effective thanclopidogrel in patients with ACS, but can induce more
minor/minimal bleeding than clopidogrel. The occurrence of
the primary efficacy endpoint was similar in the clopidogrel
groups in the ESTATE and PLATO trials (11.6% vs.
11.7%).15 When compared with the PLATO trial,15 a relative
risk reduction was observed with ticagrelor regarding the
occurrence of primary efficacy endpoint (34% vs. 16%) in
the ESTATE study, although not statistically significant.
Furthermore, ticagrelor treatment showed a tendency to
reduce the incidence of stroke in the ESTATE study, while
this was not observed in the PLATO trials. However, an
insignificant 47% increase in the relative risk of primary
efficacy endpoint was observed in the PHILO study, of which
90% of enrolled patients were Japanese.18 When all the
above results are taken together, the effect of ticagrelor
probably differs across Chinese, Japanese, and Caucasian
patient populations.
Table 4
Primary and secondary safety endpoints between the two groups during the follow-up period.
Propensity score matching () Propensity score matching (þ)
Ticagrelor
(n ¼ 324)
Clopidogrel
(n ¼ 604)
p Ticagrelor
(n ¼ 224)
Clopidogrel
(n ¼ 224)
p
Primary PLATO safety endpoint 12 (3.7) 33 (5.5) 0.23 10 (4.5) 14 (6.3) 0.40
Fatal bleeding 2 (0.6) 4 (0.7) >0.99 1 (0.4) 1 (0.4) >0.99
ICH 1 (0.3) 6 (1.0) 0.43 0 1 (0.4) >0.99
Secondary PLATO safety endpoint
Minor bleeding 20 (6.2) 17 (2.8) 0.01 14 (6.3) 7 (3.1) 0.12
Minimal bleeding 32 (9.9) 28 (4.6) 0.002 23 (10.3) 15 (6.7) 0.18
All bleeding 60 (18.5) 68 (11.3) 0.003 44 (19.6) 32 (14.3) 0.13
Bleeding sites 60 68 44 32
Ecchymosis 15 (25.0) 5 (7.4) 11 (25) 2 (6.3)
UGIB 22 (36.7) 20 (29.4) 17 (38.6) 11 (34.4)
LGIB (%) 4 (6.7) 7 (10.3) 2 (4.5) 4 (12.5)
Unknown GIB 2 (3.3) 10 (14.7) 2 (4.5) 5 (15.6)
Hematuria 4 (6.7) 7 (10.3) 4 (9.1) 4 (12.5)
Nasal 5 (8.3) 0 3 (6.8) 0
SC hematoma 2 (3.3) 0 1 (2.3) 0
ICH 1 (1.7) 6 (8.8) 0 1 (3.1)
Hemoptysis 2 (3.3) 2 (2.9) 1 (2.3) 0
Others 3 (5.0) 11 (16.2) 3 (6.8) 5 (15.6)
Dyspnea 81 (25.0) 88 (14.6) <0.001 47 (21.0) 26 (11.6) 0.01
Requiring stopping drug in dyspnea 13 (16.0) 3 (3.4) 0.01 8 (17.0) 1 (3.8) 0.15
Syncope or dizziness due to P2Y12 antagonist 1 (0.3) 3 (0.5) >0.99 1 (0.4) 1 (0.4) >0.99
Switching or discontinuing P2Y12 antagonist 70 (21.6) 94 (15.6) 0.02 37 (16.5) 10 (4.5) <0.001
Causes of switching or discontinuing
P2Y12 antagonist
<0.001 0.03
Bleeding 32 (27.1) 13 (12.1) 22 (23.9) 7 (21.9)
Dyspnea 13 (11.0) 3 (2.8) 8 (8.7) 1 (3.1)
Bradycardia or long pause 1 (0.8) 2 (1.9) 1 (1.1) 1 (3.1)
Skin reaction 0 0 0 0
Renal failure 0 0 0 0
Others 12 (10.2) 8 (7.5) 11 (12.0) 3 (9.4)
Unknown 12 (10.2) 68 (63.6) 12 (13) 13 (40.6)
Data are presented as n (%).
GIB ¼ gastrointestinal bleeding; ICH ¼ intracranial hemorrhage; LGIB ¼ low gastrointestinal bleeding; PLATO ¼ the Study of Platelet Inhibition and Patient
Outcomes; SC ¼ subcutaneous bleeding; UGIB ¼ upper gastrointestinal bleeding.
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was significantly higher with ticagrelor treatment in the
PLATO and PHILO trials (16.1% vs. 14.6% and 23.8% vs.
14.7%, respectively), but not in the current ESTATE trial
(10.3% vs. 8.9%). The lower bleeding rate observed in the
present study could be attributable to missing information or
incomplete patient records, as well as the shorter follow-up
period and retrospective nature of the study. However, in ac-
tuality, a real-world observational study enrolls a higher
number of high-risk and frail patients who are generally
excluded from prospective, randomized controlled trials. Even
so, the bleeding rates in the present study, including minimal
bleeding, are not high. Therefore, the hypothesis that a higher
bleeding risk is associated with antiplatelet treatment in the
East Asian population should be re-evaluated for the Chinese
population. Indeed, variation in the drug response of the East
Asian population remains controversial. Based on clinical
experience and evidence with anticoagulants, response to
antithrombotic treatments may be dissimilar between the
Japanese and Chinese populations.19,20 Furthermore, the
beneficial effect of pitavastatin on the metabolic profile ofJapanese patients27 could not be reproducible in either
Korean28 or Taiwanese patients.29
In addition to bleeding, a major adverse effect demanding
attention is dyspnea. The reported incidence of dyspnea with
ticagrelor treatment is around 13.8e38.6%.15,30,31 In contrast
with the very low rate of dyspnea observed in the PHILO
study,18 dyspnea was seen in 21% of the patients treated with
ticagrelor in the ESTATE study; this percentage is very similar
to that in a previous registry study.31 When compared with
clopidogrel treatment, ticagrelor causes a four-fold increase in
the incidence of dyspnea and required discontinuation of a
P2Y12 antagonist in the present study. The percentage of
affected patients observed in this study is much higher than
that of the PLATO trial; however, the clinical judgment and
discretion of a physician in a real-world setting must be
recognized as a contributing factor, as this certainly differs
from that of randomized controlled trials.
This study had several limitations, including a small sample
size as well as subdivision of patients into groups according to
propensity score matching. These limitations decreased the
statistical power of our analyses. As a result of the
Table 5
Uni- and multivariables independently predicting PLATO primary efficacy
endpoint.a
Univariables
HR (95% CI)
p Multivariables
HR (95% CI)
p
Ticagrelor use 0.56 (0.30e1.04) 0.07 d NS
Age 75 y 2.11 (1.13e3.93) 0.02
Male sex 0.20 (0.33e1.26) 0.65
DM 1.96 (1.07e3.60) 0.03
Hypertension 1.20 (0.65e2.23) 0.56
Hyperlipidemia 0.79 (0.43e1.47) 0.46
Smoking 0.60 (0.32e1.12) 0.11
Old MI 2.98 (1.38e6.45) 0.01
PCI 1.71 (0.88e3.34) 0.12
CABG 0.05 (0e9647.1) 0.63
CHF 5.38 (2.64e10.96) <0.001
PAD 1.77 (0.70e4.51) 0.23
Old CVA (ischemic) 2.96 (1.42e6.18) 0.004
CKD 2.81 (1.50e5.29) 0.001
ESRD 3.27 (1.61e6.66) 0.001 2.64
(1.29e5.41)
0.01
ACS 0.73 (0.50e1.08) 0.12
CAG on index ACS 0.20 (0.09e0.42) <0.001
PCI on index ACS 0.36 (0.19e0.69) 0.002
Stent deployment 0.37 (0.20e0.70) 0.002
ASA use 0.09 (0.05e0.17) <0.001
BB use 0.32 (0.16e0.62) 0.001
ACEI use 0.34 (0.15e0.77) 0.01
ARB use 0.72 (0.28e1.82) 0.48
Statin use 0.21 (0.11e0.39) <0.001 0.23
(0.12e0.42)
<0.001
Switching or
discontinuing
P2Y12 antagonist
0.72 (0.30e1.71) 0.45
Adherence 1.09 (0.27e4.34) 0.90
ACEI ¼ angiotensin-converting enzyme inhibitor; ACS ¼ acute coronary
syndrome; ARB ¼ angiotensin-receptor blockade; ASA ¼ aspirin; BB ¼ beta-
blockade; CABG ¼ coronary-artery bypass grafting; CAG ¼ coronary angi-
ography; CHF ¼ congestive heart failure; CI ¼ confidence interval;
CKD ¼ chronic kidney disease; CVA ¼ cerebrovascular accident;
DM ¼ diabetes mellitus; ESRD ¼ end-stage renal disease; HR ¼ hazard ratio;
MI ¼ myocardial infarction; NS ¼ nonsignificant; PAD ¼ peripheral artery
disease; PCI ¼ percutaneous coronary intervention; PLATO ¼ the Study of
Platelet Inhibition and Patient Outcomes.
a In multivariate analysis, ticagrelor use was adjusted with ESRD and statin
use only.
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could not be excluded, although multivariate adjustment and
propensity score matching were performed. Finally, we could
not exclude the possibility of selection bias, potential missing
information, and incomplete patient records.
In conclusion, to the best our knowledge, this is the first
study to evaluate the efficacy and safety of ticagrelor versus
clopidogrel in Asian patients with ACS in a real-world setting.
Ticagrelor treatment could have a marginally favorable effect
on the occurrence of MI, stroke, or vascular death at the
expense of a higher risk of dyspnea. The hypothesis regarding
higher bleeding risk with antiplatelet treatment in an East
Asian population warrants further evaluation in the Chinese
population. This pilot study provides a scientific base to call
for a larger, suitably powered Phase 4 prospective or obser-
vational study in this ethnic population.Acknowledgments
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